Elevated expression of birc6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance

Journal of Thoracic Oncology

Volumn 8, Issue 2, 2013, Pages 161-170

  Dong, Xin ^a   Lin, Dong ^a,d   Low, Chris ^a   Vucic, Emily A ^a   English, John C ^b   Yee, John ^b   Murray, Nevin ^b   Lam, Wan L ^a   Ling, Victor ^a   Lam, Stephen ^a   Gout, Peter W ^a   Wang, Yuzhuo ^a,c,d  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b Department of Pathology ^*  (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Baculoviral inhibitors of apoptosis proteins repeat containing 6; Chemoresistance; Non small cell lung cancer; Patient survival; Prognostic factor; Recurrence

Indexed keywords

BIRC6 PROTEIN; CISPLATIN; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE DOSAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 84873096103     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827d5237     Document Type: Article

References (48)

1. Boyle PaBL. World cancer report 2008. Lyon, IARC Press 2009.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
3. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355:479-485.
4. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005;172:523-529.
5. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest 2006;130:1211-1219.
6. Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-smallcell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-1277.
7. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. Apoptosis and lung cancer: a review. J Cell Biochem 2003;88:885-898.
8. Yang YL, Li XM. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 2000;10:169-177.
9. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999;13:239-252.
10. Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004;14:231-243.
11. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004;23:2009-2015.
12. Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003;9:2826-2836.
13. Shinohara ET, Gonzalez A, Massion PP, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 2005;103:1685-1692.
14. Nakahara T, Yamanaka K, Hatakeyama S, et al. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 2011;22:454-462.
15. Olie RA, Simões-Wüst AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000;60:2805-2809.
16. Bartke T, Pohl C, Pyrowolakis G, Jentsch S. Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. Mol Cell 2004;14:801-811.
17. Hao Y, Sekine K, Kawabata A, et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol 2004;6:849-860.
18. Parkinson CL, Mower JP, Qiu YL, et al. Multiple major increases and decreases in mitochondrial substitution rates in the plant family Geraniaceae. BMC Evol Biol 2005;5:73.
19. Chen Z, Naito M, Hori S, Mashima T, Yamori T, Tsuruo T. A human IAPfamily gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun 1999;264:847-854.
20. Lopergolo A, Pennati M, Gandellini P, et al. Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase- 3 activation. Br J Cancer 2009;100:739-746.
21. Sung KW, Choi J, Hwang YK, et al. Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia. Clin Cancer Res 2007;13:5109-5114.
22. Bianchini M, Levy E, Zucchini C, et al. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol 2006;29:83-94.
23. Goldstraw P. IASLC Staging Handbook in thoracic oncology. 2009.
24. Dong X, Guan J, English JC, et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 2010;16:1442-1451.
25. Wu SG, Chang YL, Lin JW, et al. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS ONE 2011;6:e23303.
26. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002;8:2912-2923.
27. Cohen D, Lane B, Jin T, et al. The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. Clin Genitourin Cancer 2007;5:264-270.
28. Zlobec I, Terracciano L, Jass JR, Lugli A. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch 2007;451:763-769.
29. Pikor LA, Enfield KS, Cameron H, et al. DNA extraction from paraffin embedded material for genetic and epigenetic analyses. J Vis Exp 2011.
30. Watson SK, deLeeuw RJ, Horsman DE, Squire JA, Lam WL. Cytogenetically balanced translocations are associated with focal copy number alterations. Hum Genet 2007;120:795-805.
31. Lockwood WW, Chari R, Coe BP, et al. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med 2010;7:e1000315.
32. Ishkanian AS, Malloff CA, Watson SK, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004;36:299-303.
33. Tsui IF, Rosin MP, Zhang L, Ng RT, Lam WL. Multiple aberrations of chromosome 3p detected in oral premalignant lesions. Cancer Prev Res (Phila) 2008;1:424-429.
34. Coe BP, Lockwood WW, Girard L, et al. Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer 2006;94:1927-1935.
35. Khojasteh M, Lam WL, Ward RK, MacAulay C. A stepwise framework for the normalization of array CGH data. BMC Bioinformatics 2005;6:274.
36. Lockwood WW, Chari R, Coe BP, et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene 2008;27:4615-4624.
37. Chari R, Coe BP, Wedseltoft C, et al. SIGMA2: a system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes. BMC Bioinformatics 2008;9:422.
38. Coe BP, Chari R, MacAulay C, Lam WL. FACADE: a fast and sensitive algorithm for the segmentation and calling of high resolution array CGH data. Nucleic Acids Res 2010;38:e157.
39. Ren J, Shi M, Liu R, et al. The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. Proc Natl Acad Sci USA 2005;102:565-570.
40. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-7190.
41. Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007;13:5995-6000.
42. Mace PD, Shirley S, Day CL. Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differ 2010;17:46-53.
43. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010;10:561-574.
44. Árvai K, Nagy K, Barti-Juhász H, et al. Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma. Pathol Oncol Res 2012;18:607-614.
45. Ismail EA, Mahmoud HM, Tawfik LM, et al. BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis. Eur J Haematol 2012;88:118-127.
46. Chu L, Gu J, Sun L, Qian Q, Qian C, Liu X. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Ther 2008;15:484-494.
47. Van Houdt WJ, Emmink BL, Pham TV, et al. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell Proteomics 2011;10:M111.011353.
48. Geiger T, Cox J, Mann M. Proteomic changes resulting from gene copy number variations in cancer cells. PLoS Genet 2010;6:e1001090.